Integrate multiple modes of biology from a single sample in a single experiment to provide transformative insights into health and disease.
Current technologies are unable to reliably resolve both genetic and epigenetic sequences at low sample input and miss important information. biomodal’s duet multiomics solution evoC gives you access to the 6-base genome – all 4 canonical bases and distinguishes 5‑methylcytosine (5mC) and 5‑hydroxymethylcytosine (5hmC) – from a single 5ng DNA sample, in a single experiment, with high accuracy.
Combined epigenetic and genetic analysis in a single sequencing run lets you access the most critical information from your DNA samples.
Better characterise liquid biopsy and genomic DNA samples of early stage cancer for diagnostic and therapy development.
Combined data reveals the role of methylation in neurodegeneration.
Pinpoint epigenetic changes that determine patterns of disease and health throughout a lifespan.
Improved DNA-based diagnostics with the ability to see disease-relevant changes from low input samples
Detect minute epigenetic changes to better understand maternal and foetal health.
A true 6-base genome that distinguishes 5mC and 5hmC together with all four canonical bases to measure multiple modes of biology
Assess all four canonical bases plus modified cytosine
Liquid biopsy represents a groundbreaking advancement in disease diagnostics, offering a less invasive alternative to traditional tissue biopsies, particularly for cancer.
Our study investigates the roles of 5‑methylcytosine (5mC) and 5‑hydroxymethylcytosine (5hmC) as biomarkers for early-stage colorectal cancer (CRC) detection in cell-free DNA (cfDNA).
The utilisation of genetic biomarkers in liquid biopsy has caused a revolution in cancer diagnostics and personalised medicine.
We can help you reveal new data and multimodal insights from your research.
